Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
about
Dynamic Viral Glycoprotein Machines: Approaches for Probing Transient States That Drive Membrane FusionHIV-1 envelope glycoprotein structureCatching HIV 'in the act' with 3D electron microscopyA Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV ImmunogenComplexes of neutralizing and non-neutralizing affinity matured Fabs with a mimetic of the internal trimeric coiled-coil of HIV-1 gp41Computational Refinement and Validation Protocol for Proteins with Large Variable Regions Applied to Model HIV Env Spike in CD4 and 17b Bound State.Native immunogold labeling of cell surface proteins and viral glycoproteins for cryo-electron microscopy and cryo-electron tomography applicationsStructural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 InfectionCrystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 EnvDevelopmental pathway for potent V1V2-directed HIV-neutralizing antibodiesPrefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopyCrystal Structure of a Soluble Cleaved HIV-1 Envelope TrimerCryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope TrimerThe crystal structure of the streptococcal collagen-like protein 2 globular domain from invasive M3-type group A Streptococcus shows significant similarity to immunomodulatory HIV protein gp41Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIVVaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesignDissociation of the trimeric gp41 ectodomain at the lipid–water interface suggests an active role in HIV-1 Env-mediated membrane fusionTrimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and GFusion of Enveloped Viruses in Endosomes.HIV-1 gp120 as a therapeutic target: navigating a moving labyrinthAntibody potency relates to the ability to recognize the closed, pre-fusion form of HIV EnvA next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodiesStructure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodiesMax Bergmann lecture protein epitope mimetics in the age of structural vaccinologyMapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular EntryAsymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies.HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentDifferential selection in HIV-1 gp120 between subtype B and East Asian variant B'.Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.Towards an integrative structural biology approach: combining Cryo-TEM, X-ray crystallography, and NMR.Spatial localization of the Ebola virus glycoprotein mucin-like domain determined by cryo-electron tomography.Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimersVisualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography.Maturation of the HIV-1 core by a non-diffusional phase transition.Automated batch fiducial-less tilt-series alignment in Appion using Protomo.Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike.Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralizationElicitation of HIV-1-neutralizing antibodies against the CD4-binding site.HIV-1 envelope protein gp41: an NMR study of dodecyl phosphocholine embedded gp41 reveals a dynamic prefusion intermediate conformation.Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies.
P2860
Q26772129-2B07BE07-D3B3-4337-B965-A69141371231Q27011248-C875DA7B-1348-4CDD-A282-7E465E4ACF1BQ27026806-F3D8F21B-F9AB-4C0E-903D-7023768287F4Q27302081-BAA2F053-6733-4F38-B1A0-E3B23FEBEFBBQ27303525-981B03C4-C644-4D42-B893-C1FB4E94D6F9Q27303608-B446A192-325C-432F-B682-C673689BEB18Q27335433-2346EAD5-2CC6-4C87-8379-27BB05609338Q27640572-74055732-77DB-468F-B5F8-A897642672C8Q27644383-2A1E5C24-09F3-4CDF-9300-28034897DE2BQ27644515-CD761414-568F-4B4D-8A08-F7DD9053CEC7Q27680442-2A0534D4-3A03-4B74-A2C3-72D7285D26D6Q27680496-15B4F6AD-1AA3-489C-85A3-5B168DDB6444Q27680497-C112FA6C-3A68-42D9-8683-DF0BD92BE184Q27680983-56C2B16A-1CF0-400B-9C90-56F45F29E958Q27681527-61376498-A6ED-4C26-926E-D0FD1280F27FQ27681806-31AEEED2-24C6-49C1-A425-8A958A8EA750Q27681827-59DB92D4-DB1E-4ABC-8349-EA32BE550650Q27704710-1F42802D-B7A9-4468-BBE4-D751B8DCD986Q28073406-1BC2A4F7-453D-4F1C-B66B-E3F7966E5D38Q28086826-5D4A3626-6E17-42AC-AEF2-9CBED6C6A4A2Q28256508-8B74A3C7-1ED9-4123-A4BB-780007783D14Q28299280-4704533F-56D0-4E18-A245-686C1C72F6DBQ28396120-1D455BC8-CFC3-4563-A6D1-B5B1A954B119Q30155145-B9887D84-95B2-4EF6-BB56-61F5B19E03FAQ30276615-E928A6C5-C8B7-4E33-846C-DB925D92A718Q30352300-E517BFD0-10EE-46E1-8B3F-789769A06BC3Q30355260-E86B28C4-1C8A-457F-845A-17C2C44B3B87Q30358184-F8973C3C-1453-44E4-B484-793C2FBE0AECQ30358736-9B73815D-B374-44BD-8213-94D30F6BC26BQ30361547-FAE20A3A-01B0-48D6-BB8B-4E8D9B435BF1Q30409973-D6B23806-F460-47C7-90B5-DBDE64FC64CBQ30580101-4C2849E3-FBCF-462D-A0B1-FF981B7F34DDQ30603475-7EA03D53-7AE3-401E-8DF6-F2BB13568911Q30613887-74F9AD5C-C102-482D-A445-1A1C04C81F7EQ30672285-4CDDB96B-5D8B-4205-88BD-957042A9BFADQ33620194-2FB33E60-3D6C-4978-8844-C3AFD676288EQ33946158-71373C96-F9E7-4802-A076-76D23F3970FFQ34133551-6FE5B22A-C01F-4E5E-87EC-86969E2DD82FQ34143321-3D635826-3DAB-4324-A31E-2B53DC5189C8Q34397758-74D8AC14-BAD7-4E6C-9068-7E8EE13158F0
P2860
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
@ast
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
@en
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
@en-gb
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
@nl
type
label
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
@ast
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
@en
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
@en-gb
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
@nl
altLabel
Structural Mechanism of Trimeric HIV-1 Envelope Glycoprotein Activation
@en
prefLabel
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
@ast
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
@en
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
@en-gb
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
@nl
P2093
P2860
P3181
P1433
P1476
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation
@en
P2093
Alberto Bartesaghi
David M Schauder
Erin E H Tran
Jacqueline L S Milne
Mario J Borgnia
Oleg Kuybeda
Sriram Subramaniam
P2860
P304
P3181
P356
10.1371/JOURNAL.PPAT.1002797
P407
P577
2012-01-01T00:00:00Z